- Repeated doses of betamethasone during pregnancy
Why this matters
- Concern over repeated doses of betamethasone in the setting of FGR may be unfounded.
- Repeated betamethasone exposure was not associated with any adverse neurocognitive effects at age 6-8 years in children with and without FGR.
- Regardless of treatment exposure, children with FGR had an increased risk of morbidity compared with those without FGR.
- Preplanned secondary analysis of the ACTORDS trial, a placebo-controlled, randomized clinical trial of repeated antenatal betamethasone administered
- Surviving children who participated in the ACTORDS trial were invited to participate and underwent physical, psychological, and neurologic exam at age 6-8 years as part of the Midchildhood Outcomes Study.
- Study participants (n=493) were compared with a control group (n=495); participants were further stratified into FGR and non-FGR groups.
- Funding: National Health Medical Research Council of Australia, Health Research Council of New Zealand, Auckland Medical Research Foundation.
- Small numbers in study.
- FGR defined as less than a third percentile.